乙型/Victoria 抗原在两剂乙型/Yamagata 疫苗接种的儿童中诱导强烈的 Β/Yamagata 回忆反应，但乙型/Victoria 反应较低。

Influenza Β/Victoria antigen induces strong recall of Β/Yamagata but lower Β/Victoria response in children primed with two doses of Β/Yamagata.

机构信息

British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.

出版信息

Pediatr Infect Dis J. 2011 Oct;30(10):833-9. doi: 10.1097/INF.0b013e31822db4dc.

DOI:10.1097/INF.0b013e31822db4dc

PMID:21857263

Abstract

OBJECTIVES

Trivalent inactivated influenza vaccine (TIV) contains 1 of 2 influenza B/lineages (B/Yamagata or B/Victoria) annually. We assessed prime-boost responses in young children following a change in the B/lineage included in TIV.

METHODS

Participants were primed during a clinical trial as infants or toddlers with two 0.25 or two 0.5 mL doses of 2008-2009 TIV containing B/Florida/4/06(Yamagata) antigen. In subsequent years, sequential subsets received annual age-appropriate doses of 2009-2010 and 2010-2011 TIV containing the changed influenza B/lineage antigen (B/Brisbane/60/08(Victoria)). Serologic response was assessed pre- and postimmunization by hemagglutination inhibition (HI; with/without ether treatment of influenza B antigen) and microneutralization. The primary immunogenicity outcome was the seroprotection rate (SPR) measured by HI without ether treatment (SPR:HI titers ≥40).

RESULTS

Fifty-six children were included in 2009-2010 and 36 in 2010-2011 analyses. Before the 2009-2010 TIV dose, antibody to all 2008-2009 TIV components had fallen to low levels: SPR <10% for B/Florida/4/06(Yamagata) and B/Brisbane/60/08(Victoria) antigens. A single 2009-2010 TIV dose boosted antibody to the shared 2008-2009/2009-2010 influenza A antigens and to the priming 2008-2009 B/Florida/4/06(Yamagata) antigen with SPRs >85%. In contrast, antibody to the B/Brisbane/60/08(Victoria) antigen included in the 2009-2010 TIV remained low: SPR <25%. Antibody to the B/Brisbane/60/08(Victoria) antigen was not improved from a further dose in the 2010-2011 TIV: SPR 31% versus SPR 69% to B/Yamagata. A similar pattern of B/Yamagata dominance was observed when HI testing was conducted with antigen prepared by ether treatment.

CONCLUSIONS

Repeated annual TIV doses containing B/Victoria-lineage antigen strongly recalled antibodies to the B/Yamagata antigen of first exposure, but elicited lower B/Victoria responses.

摘要

目的

三价灭活流感疫苗（TIV）每年包含 1 种流感 B/系（B/Yamagata 或 B/Victoria）。我们评估了 TIV 中 B/系变化后对幼儿的初免-加强免疫反应。

方法

参与者在临床试验中作为婴儿或幼儿接受了两次 0.25 或两次 0.5 毫升 2008-2009 年 TIV 的免疫接种，其中含有 B/Florida/4/06（Yamagata）抗原。在随后的几年中，连续的亚组每年接受了含有变化的流感 B/系抗原（B/Brisbane/60/08（Victoria））的 2009-2010 年和 2010-2011 年 TIV 的年龄适宜剂量。免疫前和免疫后通过血凝抑制（HI；用/不用乙醚处理流感 B 抗原）和微量中和试验评估血清学反应。主要免疫原性结果是 HI 测量的血清保护率（SPR），未经乙醚处理（SPR：HI 滴度≥40）。

结果

56 名儿童被纳入 2009-2010 年分析，36 名儿童被纳入 2010-2011 年分析。在接受 2009-2010 年 TIV 剂量之前，针对所有 2008-2009 年 TIV 成分的抗体均已降至低水平：针对 B/Florida/4/06（Yamagata）和 B/Brisbane/60/08（Victoria）抗原的 SPR<10%。单次 2009-2010 年 TIV 剂量可增强对共同的 2008-2009/2009-2010 年流感 A 抗原和 2008-2009 年 B/Florida/4/06（Yamagata）抗原的抗体反应，SPR>85%。相比之下，2009-2010 年 TIV 中包含的 B/Brisbane/60/08（Victoria）抗原的抗体仍保持较低水平：SPR<25%。在 2010-2011 年 TIV 中进一步给予剂量后，B/Brisbane/60/08（Victoria）抗原的抗体并未得到改善：SPR 31%对 B/Yamagata 的 SPR 69%。当用经乙醚处理的抗原进行 HI 检测时，观察到 B/Yamagata 优势的类似模式。